{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T00:10:21Z","timestamp":1734912621688,"version":"3.32.0"},"reference-count":5,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T00:00:00Z","timestamp":1722902400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,23]]},"abstract":"<jats:p>This retrospective review assessed adjuvant intravenous immunoglobulin (IVIG) treatment in six patients with refractory pyoderma gangrenosum (PG). All patients reported decreased ulcer size or depth, with one achieving complete healing. Most had a reduction in pain, and an increase in pain coincided with disease flares. IVIG was well tolerated, although two patients required hospitalization for infection management. Results suggest that IVIG is a safe and effective option for refractory PG, with pain reduction potentially serving as a marker for treatment response, although recurrence remains a concern.<\/jats:p>","DOI":"10.1093\/ced\/llae318","type":"journal-article","created":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T14:09:55Z","timestamp":1722694195000},"page":"167-169","source":"Crossref","is-referenced-by-count":0,"title":["Review of adjuvant intravenous immunoglobulin treatment in patients with refractory pyoderma gangrenosum: a single-centre experience"],"prefix":"10.1093","volume":"50","author":[{"given":"Charlotte","family":"Krones","sequence":"first","affiliation":[{"name":"Dermatology Department, Western Health , Melbourne, VIC ,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gia T","family":"Tang","sequence":"additional","affiliation":[{"name":"Dermatology Department, Western Health , Melbourne, VIC ,","place":["Australia"]},{"name":"Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne , Melbourne, VIC ,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Scardamaglia","sequence":"additional","affiliation":[{"name":"Dermatology Department, Western Health , Melbourne, VIC ,","place":["Australia"]},{"name":"Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne , Melbourne, VIC ,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,8,6]]},"reference":[{"key":"2024122223562208800_llae318-B1","first-page":"81","article-title":"Pyoderma gangrenosum","volume-title":"Nat Rev Dis Primers","author":"Maverakis","year":"2020"},{"key":"2024122223562208800_llae318-B2","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/ajd.14024","article-title":"Intravenous immunoglobulin treatment for refractory pyoderma gangrenosum","volume":"64","author":"Nguyen","year":"2023","journal-title":"Australas J Dermatol"},{"key":"2024122223562208800_llae318-B3","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1111\/j.1365-2133.2007.08433.x","article-title":"Intravenous immunoglobulin for pyoderma gangrenosum","volume":"158","author":"Kreuter","year":"2008","journal-title":"Br J Dermatol"},{"key":"2024122223562208800_llae318-B4","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jaad.2018.02.007","article-title":"The impact of underlying disease state on outcomes in patients with pyoderma gangrenosum: a national survey","volume":"79","author":"Kaffenberger","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"2024122223562208800_llae318-B5","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1001\/jamadermatol.2023.3115","article-title":"Pain as a patient-reported outcome measure in pyoderma gangrenosum","volume":"159","author":"Erickson","year":"2023","journal-title":"JAMA Dermatol"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llae318\/60048528\/llae318.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/1\/167\/60048528\/llae318.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/1\/167\/60048528\/llae318.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,22]],"date-time":"2024-12-22T23:56:30Z","timestamp":1734911790000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/50\/1\/167\/7728034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,6]]},"references-count":5,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,8,6]]},"published-print":{"date-parts":[[2024,12,23]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llae318","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"type":"print","value":"0307-6938"},{"type":"electronic","value":"1365-2230"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2024,8,6]]}}}